Overview

Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to characterize the steady state plasma
Phase:
Phase 4
Details
Lead Sponsor:
Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.
Treatments:
Rifamycins
Rifaximin